INTRODUCTION
Second primary malignancies (SPMs) represent 15% to 20% of all newly diagnosed cancers in the Western world. 1, 2 Advances in treatment and supportive care have resulted in substantial improvements in cancer survival and in a growing number of cancer survivors in the United States alive to develop SPMs; this number is estimated to become 20 million in 2026. 3 SPMs are likely due to a combination of genetic factors, carcinogenic effects of cancer treatment, common exposures (eg, tobacco), and other as yet unknown factors, with higher risks among those diagnosed with their first cancer as children or adolescents and young adults (AYAs). 4, 5 The burden of SPMs in AYAs is high, with the excess risk of SPMs higher in this age group than younger or older cancer survivors. 4 Although the risk factors for the development of SPMs after certain malignancies has been well described, little research has explored the impact of SPMs on survival. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In childhood cancer survivors, SPMs are the most common cause of mortality among 5-year survivors. 19 Our recent article 12 also showed that the adverse impact of SPMs on survival is substantial for AYA survivors (ie, those 15-39 years old) and may explain some of the lack of survival improvement in AYAs versus other age groups. This study demonstrated that relative survival by SPM status was worse for younger survivors versus older survivors and for certain types of SPMs. 12 However, we did not previously account for latency between primary and subsequent malignancies, which has been hypothesized to affect survival, with earlier occurring SPMs having a more negative survival impact than SPMs that develop much later during the survival period. 20, 21 As the 2014 Cancer Survivorship Summit of the European Organization for Research and Treatment of Cancer made "elucidating survival after SPMs" a research priority in the field of late effects of cancer, 2 the current study evaluates the effect of the latency time on survival for AYAs with an SPM.
MATERIALS AND METHODS

Patients and Study Variables
All patients aged 15 to 39 years who had been diagnosed with a histologically confirmed, invasive, AYA SPM (with a known type of first invasive malignancy) during 1992-2008 were identified from 13 registries in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, which includes approximately 13% of the US population. 22 We included diagnoses up to 2008 to permit at least 5 years of follow-up for all patients. Patients diagnosed with a primary malignancy (PM) at an age < 15 years who had an SPM as an AYA were also included to capture the entire spectrum of AYA SPMs. Patients who had third and fourth SPMs were also included as long as their second cancer occurred when they were an AYA. As done previously, we focused our analysis on common cancers reported in the US AYA population: acute leukemia (acute lymphoid and myeloid), lymphoma (Hodgkin and non-Hodgkin), sarcoma (soft-tissue and bone), colorectal cancer, female breast cancer, central nervous system (CNS) cancer, melanoma, cervical cancer, thyroid cancer, and germ cell cancer (testicular and ovarian). 12 The SEER AYA recode, based on the AYA classification suggested by Barr et al 23 and updated on the basis of histology changes in the World Health Organization hematopoietic/lymphoid tissue book, 24 was used primarily to determine histologic types of cancer. For those primary sites not individually designated in the AYA recode listing (testicular, cervical, CNS, and colorectal cancers), we used the SEER site recode (International Classification of Diseases for Oncology, Third Edition/World Health Organization 2008).
From the SEER database, we obtained information routinely recorded in the medical record at diagnosis for each patient: age, sex, race/ethnicity (non-Hispanic white [hereafter called white]), Hispanic, black, Asian or Pacific Islander, American Indian or Alaska Native, or unknown), summary stage for each malignancy, year of diagnosis of the second cancer, geographic region, socioeconomic status (divided by quartiles based on the county-level median income for all AYAs who developed an SPM), and sequence of the primary cancer. Two variables were categorized for more in-depth analysis: the age at diagnosis of the first cancer (<15, 15-25, or 26-39 years) and the latency (the time between the first and second cancers; 1-5 or 6 years). In addition, we obtained the vital status (routinely determined through hospital follow-up and linkages to state and national vital status and other databases) and, for the deceased, the underlying cause of death.
SPMs diagnosed within 12 months of the PM were excluded to remove what were likely multiple primary and synchronous tumors, which likely had different biologies and etiologies, and to address the question of latency. SPMs with histologies similar to those of their corresponding PM were also individually reviewed to verify that no SPMs would be considered recurrences according to the updated multiple primary coding rules and clinical practice, as we did in our previous study. 12, 25 Specifically, lymphoma, leukemia, bone sarcomas, ovarian cancer, thyroid carcinoma, CNS cancer, and cervical cancer with the same histology as the first primary were not considered SPMs. Soft-tissue sarcomas were considered SPMs if the primary site or histology was different from that of the first primary. Testicular cancers were considered SPMs only if the histology or laterality was different from that of the PM. Female breast carcinomas were considered SPMs only if the histology was different from that of the PM, if it occurred in the contralateral breast, or if it occurred >5 years after the first primary. Colorectal cancers were considered SPMs only if the histology was different from that of the PM or if it occurred >1 year after the first primary. All melanomas were considered SPMs according to definitions used in previous publications on melanoma second primaries. 26 Patients with an invalid survival time (n 5 378) were also excluded. This study was approved by University of California, Davis Institutional Review Board.
Statistical Analysis
The primary outcomes of this study were cancer-specific survival (CSS) from any cancer and CSS from the first and second malignancies. We also considered death from all causes for analyses with all AYAs. To determine whether the latency time between the PM and the SPM had an independent effect on survival, we used multivariate Cox proportional hazards regression models to estimate hazard ratios (HRs) and associated 95% confidence intervals (CIs). Multivariate models included the age at diagnosis of the first primary, sex, race/ethnicity, summary stage at diagnosis for each malignancy, year of diagnosis of the SPM, and, for analyses of all AYAs, cancer type. For deceased patients, the survival time was measured in months from the date of diagnosis of the selected first PM or SPM to the date of death from any cancer or the specific first or second cancer. Patients who died of other causes were censored at the time of death in analyses of CSS. For analyses of overall survival among all AYAs, the survival time was measured in months from the date of diagnosis of the selected first PM or SPM to the date of death from any cause. Patients alive at the study end date (December 31, 2013) were censored at this time or at the date of last known contact. In all models, the proportional hazards assumption was assessed numerically on the basis of cumulative sums of martingale residuals 27 and was visually based on an inspection of the survival curves [2log(2log ()) of survival function (months) by log (months)]. Variables that violated this assumption were included as stratification variables in the models (see the footnotes of the tables). All calculations were performed with SAS software (version 9.3; SAS Institute, Inc, Cary, North Carolina).
RESULTS
Of 1515 AYA patients with an SPM, the majority had their PM diagnosed between the ages of 26 and 39 years (74.2%) and their SPM diagnosed 1 to 5 years later (72.9%; Table 1 ). There were more females (61.4%) than males, and a distribution of race/ethnicities as well as socioeconomic backgrounds was represented. The most common PMs in AYAs who developed an SPM were breast cancer, germ cell cancer, and leukemia or lymphoma, and the majority of nonleukemia primary tumors (61.0%) were localized at diagnosis. Many patients with a subsequent breast, germ cell, or colorectal malignancy had a PM of the same type versus a smaller proportion of lymphomas (23%) or leukemias (34%).
The median follow-up time for all AYAs in the study was 11.4 years (range, 1.1-21.9 years) after their PM. Overall, those who developed an SPM 1 to 5 years (vs 6 years) after a PM diagnosis had an independent, more than 2-fold increased risk of death from cancer (HR, 2.52; 95% CI, 1.92-3.29) and all causes (HR, 2.60; 95% CI, 2.04-3.32; Table 2 ). Moreover, when CSS was evaluated separately for first and second cancers, the increased risk of death from cancer due to a shorter latency multiplied to more than 6-fold (HR for PM CSS, 6.36; 95% CI, 3.70-10.95; HR for SPM CSS, 6.7495% CI, 4.27-10.65). The results were similar in a sensitivity analysis that excluded all patients whose SPM was the same cancer type as their PM (Supporting Table  1 [see online supporting information]). Depending on the type of SPM, shorter latency decreased CSS up to 9-fold for all SPMs except sarcoma (Supporting Table 2 [see online supporting information]).
AYAs who developed a leukemia, breast, colorectal, or CNS SPM and died did so most commonly because of that malignancy and not because of their PM or an unrelated cause of death (Table 3 ). Moreover, for these patients, a shorter latency of 1 to 5 years (vs 6 years) from their PM diagnosis was associated with an independent, significantly increased risk of death from either their PM or that particular SPM. The magnitude of the impact of this shorter latency for these SPM patients is shown for secondary acute leukemia (HR for PM, 3 Table  3 ). In addition, latency affected the overall CSS for AYAs with lymphoma (Supporting Table 2 [see online supporting information]), although it did not significantly affect the CSS with respect to either the PM or SPM. No associations between latency and survival were observed for AYA patients with sarcoma SPMs. Multivariate survival models are not presented for thyroid, germ cell, cervical, or melanoma SPMs because of the small number of patients who died of these SPMs (0, 7, 8, and 14, respectively).
Patients of Hispanic race/ethnicity (vs whites), patients older than 25 years at their first malignancy, and those with a more advanced or unknown stage of either malignancy at diagnosis (vs a localized stage) also had an increased risk of death (Table 2 ). When we evaluated specific tumor types, an older age at the diagnosis of the PM was associated with improved CSS for patients with a secondary sarcoma but decreased CSS from the PM for patients with a breast SPM (Table 3) . Distant disease at the diagnosis of a colorectal SPM appeared to have a significant impact on the CSS with respect to both the PM and the colorectal SPM, whereas only a regional stage of disease for the PM decreased the CSS with respect to both the PM and the colorectal SPM. For breast SPMs, a diagnosis of regional-or distant-stage disease for the PM and the breast SPM decreased CSS. For patients with a lymphoma SPM, distant disease at the diagnosis of the PM decreased CSS with respect to both the PM and the SPM. In addition, AYAs of Hispanic ethnicity (vs white AYAs) with secondary leukemia, lymphoma, sarcoma, or breast cancer had an increased risk of death from their SPMs. The results were generally similar in analyses of any CSS (Supporting Table 1 Other pediatric malignancies included malignancies of the oral cavity and pharynx, digestive system (except colorectal cancer), respiratory system, urinary system, and eye and orbit.
Original Article side effects of environmental exposures, or from unknown etiologies. Because patients are living longer lives as cancer survivors, the proportion of survivors who develop an SPM continues to increase. However, there is little research on what impact SPMs have on survival. The current study details the negative influence that a shorter latency time to the development of an SPM has on both CSS and overall survival in AYAs. SPMs that developed within 1 to 5 years-approximately 90% of all SPMs in AYAs-led to a 2-to 9-fold increased risk of cancerspecific death, depending on the type of SPM. Shorter latency between cancers as well as the development of an SPM can be secondary to treatment or due to host factors, whereas longer latency is more likely to be treatment-related or spontaneous. 2, 19, [28] [29] [30] Only 2 other studies in the literature have evaluated the impact of latency on survival, but both involved pediatric cancer cohorts. The first used SEER cancer registry data and looked only at SPMs that developed before the age of 20 years among children who were diagnosed with a first primary solid tumor. As in the current study, the development of an SPM among these patients was associated with lower 5-and 10-year overall survival, with the greatest decrease in overall survival coming when the SPM was a leukemia or lymphoma (followed by CNS, sarcoma, carcinoma, and skin cancer). 20 A latency of less than 5 years was associated with significantly lower 5-(36% vs 100%) and 10-year overall survival rates (26% vs 86%; P 5 .0001), but the authors did not consider multivariate-adjusted rates or CSS for either the PM or the SPM. The second study, involving 5-year childhood cancer survivors from the Childhood Cancer Survivorship Study, found a more then 15-fold increased hazard of death due to an SPM, which was more than 2 times the risk of death from any other medical late effect (ie, cardiac, pulmonary, or other medical causes). 21 The shorter the latency was (starting at 5 years after the diagnosis of the PM), the higher the HR and the absolute excess risk of death from SPMs were. By 20 years of follow-up, the death rate due to SPMs exceeded the death rate due to recurrence.
A handful of publications have compared survival with PMs and SPMs of the same type in AYAs. [31] [32] [33] [34] All showed an increased risk of death if a tumor occurred as an SPM versus a primary cancer, although few evaluated whether death was due to the PM or SPM. A few studies of older adult populations of either prostate or renal cell carcinoma survivors compared survival for patients who did and did not develop an SPM. [35] [36] [37] [38] None demonstrated a difference in CSS in this older cohort, but they The primary strength of the current study is the large number of patients able to be captured from a population-based registry with a median follow-up of nearly 11.5 years; this strengthens the generalizability of our results. However, there are limitations that are consistent with those of large registries and studies that require a very long follow-up time for complete catchment of data. These include a lack of complete, detailed treatment information and genetic analyses, including information on hereditary cancer syndromes, which are known to decrease survival in many instances, and lifestyle factors, such as smoking. In addition, the cause of death comes from death certificate information, which previous studies have shown to have inaccuracies. 39 Moreover, younger populations, particularly AYAs, tend to be more mobile, and this may lower the number of SPMs identified because subsequent cancers are not recorded for patients who migrate from their original geographic areas. Also, many SPMs, especially radiation-induced solid tumors, are not diagnosed until more than 15 to 20 years after the PM and, therefore, would not be captured in our analyses. 40, 41 This leads to under-ascertainment of SPMs because during longer follow-up many more survivors would develop an SPM and, therefore, conservative overestimates of cancer survival. There is also a potential healthy-survivor selection bias, by which only patients less likely to die of PM-related causes of death, including toxic death, survived to develop an SPM. Lastly, there is the possibility that including SPMs of the same type as the PM may reflect relapsed disease rather than an SPM; however, when we excluded these patients from our analyses, our results were essentially unchanged.
In conclusion, most AYAs who develop an SPM do so within 1 to 5 years of their primary cancer diagnosis, and they have an increased risk of death from cancer in comparison with AYAs who develop an SPM after longer survivorship intervals. Although the exact etiology of this remains unknown, we hypothesize that this may be a reflection of an individual's inherent genetic/biologic makeup that is more prone to multiple and more aggressive cancers. This suggests that both SPM surveillance strategies and SPM treatment might be tailored in this age group according to the latency time from the primary diagnosis and the type of SPM to improve outcomes after SPMs. Moreover, future research could be directed toward the prevention of early SPMs in this age group.
